Protagonist Therapeutics
PTGX
85 hedge funds and large institutions have $605M invested in Protagonist Therapeutics in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 14 reducing their positions, and 17 closing their positions.
267% more capital invested
Capital invested by funds: $165M → $605M (+$440M)
200% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 14
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
13.81% more ownership
Funds ownership: 85.66% → 99.47% (+14%)
10% more funds holding
Funds holding: 77 → 85 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$27.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$21M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.4M |
| 4 |
DM
Deerfield Management
New York
|
+$12.7M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.71M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.31M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$1.61M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.12M |
| 5 |
VA
VR Adviser
New York
|
-$799K |
PTGX Hedge Fund Activity: Q2 2020 in Review
85 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2020, worth a combined $605M — up 267% from $165M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PTGX positions and 17 closed out — a net gain of 8 holders — while 42 added to existing stakes and 14 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $27.6M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.71M sold.
- 85 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2020, up from 77 in Q1 2020.
- Funds reported $605M of Protagonist Therapeutics stock for Q2 2020, up 267% quarter-over-quarter.
- 25 funds opened new Protagonist Therapeutics positions in Q2 2020 and 17 closed out, a net change of +8 holders.
- The largest Protagonist Therapeutics buyer in Q2 2020 was Adage Capital Partners, an estimated $27.6M added.
- The largest Protagonist Therapeutics seller in Q2 2020 was Sphera Funds Management, an estimated $3.71M sold.
Based on aggregated 13F filings for Q2 2020.